TEHRAN (ANA)- Iranian researchers at a knowledge-based company succeeded in producing the drug ‘Trastuzumab’ used for the treatment of breast and stomach cancers.
One of the products that has been indigenized by the knowledge-based company and will make the country needless of similar foreign drugs, is ‘AryoTrust’ with the generic name ‘Trastuzumab; a recombinant monoclonal antibody directed against the human epidermal growth factor receptor II. This receptor is naturally present on the surface of normal cells and regulates cell growth and proliferation.
“The main field of activity of our company is the production of special drugs like cancer and MS drugs, and AryoTrust is one of the newest products of our company. This drug is similar to the Iran-made drug Herceptin and the main purpose of producing the drug is to treat breast cancer,” said Mohammadreza Yazdannasab, a clinical studies expert at the company.
Noting that the drug is now in the phase of clinical studies and will receive the export license after this stage, he said, “At present, we are studying the impacts of the drug in the fourth phase of clinical studies. This phase is one of the official phases approved by the Iranian and foreign regulators to see the side effects on the unscreened population, and we are cooperating with various doctors across the country.”
Yazdannasab said that after mass-production of AryoTrust, all needs to the drug will be met in the country.
In a relevant development in December, Iranian Vice-President for Science, Technology and Knowledge-Based Economy Rouhollah Dehqani Firouzabadi had unveiled the domestically-developed production line of the injectable anti-cancer drug, cyclophosphamide, at an Iranian knowledge-based company.
Addressing the unveiling ceremony, Dehqani Firouzabadi said the country needs nearly 400,000 doses of the drug every year that will be sufficiently met with the new production line.
Cyclophosphamide is used to treat a wide range of cancers, including blood and ovarian cancers.
Also, Mehdi Abbasi, the head of Alborz Park of Science and Technology, which hosts the knowledge-based Nano Alvand company, underlined the positive effects of the new drug in treating a wide range of cancer types.
“This injectable anti-cancer drug is used to treat patients suffering from various types of cancer, including leukemia, ovarian, breast and eye cancer,” he said.
Abbasi underlined that by launching the production line of cyclophosphamide, the country does not need to import the drug anymore.
4155/v
Source: ANA